THC/CBD Combo Cuts Agitation in Hospice Dementia Patients: LiBBY Trial

Trial Design and Patient Population

The LiBBY trial enrolled 184 hospice-eligible dementia patients across 22 U.S. facilities, randomizing them to receive either a 1:1 THC/CBD sublingual formulation or placebo over 12 weeks. Hospice-eligible status meant patients had a median life expectancy under six months and Functional Assessment Staging Test (FAST) scores of 7c or higher, indicating severe cognitive decline. The primary endpoint was change in Cohen-Mansfield Agitation Inventory (CMAI) score from baseline to week 12.

Patients received escalating doses starting at 2.5 mg THC / 2.5 mg CBD twice daily, titrated to effect up to a maximum of 10 mg / 10 mg twice daily. Median final dose was 7.5 mg / 7.5 mg twice daily. Caregivers administered the sublingual oil 30 minutes before typical agitation triggers—bathing, dressing, or evening sundowning.

Agitation Scores Dropped 34% in Treatment Arm

The THC/CBD group saw a mean 34% reduction in CMAI scores versus 12% in placebo, a difference that reached statistical significance (p < 0.001). The effect size was largest in patients with physical aggression subscores, where the treatment arm showed a 41% decline compared to 9% in placebo. Verbal agitation showed a smaller but still significant 28% reduction.

Secondary endpoints included caregiver burden (measured by Zarit Burden Interview) and rescue medication use. Treatment patients used 52% fewer PRN doses of haloperidol or lorazepam during the trial period. Caregiver burden scores improved by 19 points in the THC/CBD arm versus 6 points in placebo.

Safety Profile: No Serious Adverse Events Attributed to Cannabinoids

No serious adverse events were attributed to the THC/CBD formulation, and dropout rates were comparable between arms (14% treatment, 16% placebo). Mild sedation was the most common side effect, reported in 22% of treatment patients versus 11% of placebo. Dry mouth affected 18% versus 8%. No cases of respiratory depression, falls with injury, or delirium were linked to the cannabinoid therapy.

Exclusion criteria narrowed generalizability: the trial barred patients with active cannabis use disorder or those on high-dose benzodiazepines. Median survival post-enrollment was 4.1 months in both arms, suggesting the treatment didn't hasten or delay death.

Market Implications: Palliative-Care Wedge for Medical Cannabis

The bull case: hospice and palliative-care formularies represent a defensible, Medicare-adjacent niche where cannabinoids face minimal competition from FDA-approved alternatives. Current standard of care for dementia agitation relies on antipsychotics with black-box warnings in elderly patients. A THC/CBD product positioned as a harm-reduction alternative could command premium pricing in hospice pharmacy channels.

The bear case? Medicare Part D doesn't cover Schedule I substances, and hospice reimbursement rates are fixed per diem, leaving little budget for add-on therapies. Without federal rescheduling or a carve-out for end-of-life use, adoption will be confined to cash-pay or state Medicaid programs in medical cannabis states. The trial sponsor, a Canadian biotech, hasn't disclosed U.S. commercialization plans.

Regulatory Path Unclear Absent Rescheduling

The LiBBY trial was conducted under an FDA Investigational New Drug (IND) application, but the path to approval remains blocked by THC's Schedule I status. The sponsor would need to file a New Drug Application (NDA) supported by two pivotal trials, a process that typically takes 18-24 months post-submission. Even with positive Phase 3 data, the FDA can't approve a Schedule I drug without DEA rescheduling or congressional action.

These results arrive as the DEA's proposed rescheduling of cannabis to Schedule III remains stalled in administrative review. If rescheduling proceeds, the LiBBY data could support an expedited approval pathway under FDA's 505(b)(2) route, using existing safety data on Epidiolex (CBD) and Marinol (synthetic THC). For full background on the federal rescheduling process, see the CannIntel topic hub on cannabis and dementia research.

What to Watch: Phase 3 Timeline and Partnership Signals

The sponsor hasn't announced a Phase 3 timeline or disclosed whether it'll seek a U.S. partner with hospice-pharmacy distribution infrastructure. Investors will be watching for licensing deals with established palliative-care drug makers or specialty distributors. Next catalyst? Any DEA movement on rescheduling, which would unlock the regulatory pathway and shift the risk/reward calculus for late-stage cannabinoid trials.

Comparable companies in the cannabinoid-pharma space—Jazz Pharmaceuticals (Epidiolex), Insys (defunct Syndros franchise)—have faced reimbursement headwinds even with FDA approval. The LiBBY trial's focus on a narrow, high-need population may offer a cleaner commercial narrative. But execution risk remains high without federal policy change.